Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Haematologica|May 12, 2018
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapyMarek Trnĕný, Gregor Verhoef, Martin Js Dyer, et al.
The New England Journal of Medicine|July 13, 2022
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's LymphomaStephen M Ansell, John Radford, Joseph M Connors, et al.
The Lancet. Oncology|February 23, 2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trialMarek Trněný, Thierry Lamy, Jan Walewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2023
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical TrialJuan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, et al.
Blood|January 10, 2016
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma studySally F Barrington, Amy A Kirkwood, Antonella Franceschetto, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.
Oncotarget|January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Pageof 11